The eradication rate of standard triple therapy was affected by the history of smoking (P = 0.033), presence of peptic ulcer (P = 0.002), and clarithromycin resistance (P < 0.001), but not by host CYP2C19 genotype and other clinical factors (Table 4). This evidence concerns the gene CYP2C19 and Peptic ulcer.